Michael Sargent Binkley
@michaelsbinkley
ID:1250057182017507328
14-04-2020 13:43:59
163 Tweets
209 Followers
139 Following
Let's take your mind on a walk outside the box.
Phase I Clinical Trial of SBRT for Lung Volume Reduction for Severe Emphysema
Max Diehn, MD/PhD Bill Loo MD PhD ⚡️☢️ Stanford Radiation Oncology
At: redjournal.org/article/S0360-…
Great example of innovation that can come from collaboration between #RadOnc and Thoracic Surgery. Idea inspired by emphysema LVRS practice of Dr. Joe Shrager. Excellent work on primary analysis of this first in human trial by Devanish Kamtam and Michael Sargent Binkley. Stanford Radiation Oncology
International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma: important work by my Wilmot Cancer Institute colleague Jamie Flerlage Journal of Clinical Oncology
ascopubs.org/doi/full/10.12…
Thank you kristac and Stanford Medicine for highlighting our recent work in Nature Cancer investigating the soft tissue #sarcoma microenvironment!
med.stanford.edu/news/all-news/…
Monumental effort by GLOW team in publishing the largest analysis of NLPHL to date and answering many key questions about age specific risks, the prognostic impact of variant patterns, and developing a new LP-IPS: ascopubs.org/doi/10.1200/JC… GLOW: Global nLPHL One Working Group Journal of Clinical Oncology Jamie Flerlage
I'm seeking a computational postdoc for my team Stanford Radiation Oncology! We're building ML tools to crack genomic data for enhancing early cancer detection (and more). Join us!🧬💻 Please RT!
postdocs.stanford.edu/prospective/op…
SCI member Everett Moding & others define the landscape of diverse malignant and stromal cell states within #SoftTissueSarcoma & patient response to #immuotherapy . go.nature.com/3TkzYtg Everett Moding, MD, PhD
Thank you to all our co-authors who made this work possible! david van ijzendoorn Bogdan Luca Maggie Zhou Michael Sargent Binkley Sandra P D'Angelo, MD William Tap Matt van de Rijn Kristen Ganjoo Nam Bui Greg Charville Aaron Newman Lab
11/12
Radiation-associated grade ≥3 adverse cardiac events occur in more than 20% of individuals undergoing thoracic RT within a median time frame of <2 years. Dr. Hyunsoo Joshua No, MD, CMD, et al observed an elevated cardiac event risk following thoracic RT. bit.ly/3rvQvzA #JACCCardioOnc
📰JACC Journals #JACCCardioOnc
🫀Post-treatment cardiotoxicity is a leading cause of morbidity & mortality in long-term cancer survivors. In this study, Hyunsoo Joshua No, MD, CMD & team explore dosimetric & imaging markers to predict CV events after RT.
➡️tinyurl.com/yc7shz2s
#CardioOnc
Our prospective observational study NLPHLPRO is now open at St. Jude Research! We are studying quality of life and patient-reported outcomes in patients with NLPHL.
Congratulations to PIs Drs. Ajay Major, MD, MBA, Dr. Valerie Crabtree, and Anna Jones. #NLPHLsm #lymsm
clinicaltrials.gov/study/NCT06098…
Excited to report our recent study regarding the prognostic implication of CHIP among MM patients undergoing HCT with SaroArmenian City of Hope, published in JAMA Cardiology. We asked whether CHIP detected at the time of HCT is associated with increased risk of CVD among MM patients.
Dr. Appel presents at #ISCAYAHL23 about the GLOW: Global nLPHL One Working Group consortium and our ongoing plans to design and execute a deintensification-oriented multinational clinical trial for early-stage NLPHL. #lymsm #NLPHLsm
🙌eJHaem Journal is pleased to publish a special issue on ' #Lymphoma in adolescents and young adults: Navigating a path forward together'
The series includes an editorial & 7 associated mini-reviews on key & timely topics covering #AYA lymphomas.
👉SEE: onlinelibrary.wiley.com/doi/toc/10.100…
1/3
📢Thank you JACC Journals #JACCCardioOnc for publishing our work!
Post-tx Cardio dz is a leading cause of morbidity & mortality in long term cancer survivors. Our study looks into dosimetric & imaging markers predicting cardiac events post thoracic RT.
bit.ly/3rvQvzA
Big news day in #lymsm #lymphoma ! Congratulations Katharine Lewis Chan Cheah et al for leading this massive international effort
High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma ascopubs.org/doi/10.1200/JC…
#ASTRO23 #JACCCardioOnc SimPub: #MACE occurs in >20% of those undergoing RT in a median time of <2 yrs. In this article, Hyunsoo Joshua No, MD, CMD, et al exhibit the use of coronary artery dosimetry & imaging biomarkers to help predict MACE risk & inform personalized RT bit.ly/3rvQvzA
IJROBP - The Red Journal Belinda Campbell Mayo Clinic Comprehensive Cancer Center ILROG Team Many thanks IJROBP - The Red Journal for the invitation to share our experience with peri-transplant RT in relapsed/refractory HL. Belinda Campbell ILROG Team FIL_ETS Mayo Clinic Comprehensive Cancer Center